Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01459588 · ClinicalTrials.gov registry record · Phase 3

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

A Phase 3 study of Dry Eye Syndromes, sponsored by Allergan.

Completed
Registry status
Phase 3
Development phase
315
Enrollment target
1
Study location

NCT01459588 is a Phase 3 study of Dry Eye Syndromes that has completed, run by Allergan. The registered enrollment target is 315 participants, below the 396-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01459588, a Phase 3 study of Dry Eye Syndromes, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 3
Development phase
315 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the safety, efficacy, and acceptability of an eye drop formulation in subjects with dry eye disease.

Conditions Studied

Interventions

  • DRUG Carboxymethylcellulose Based Eye Drop Formulation A
  • DRUG Carboxymethylcellulose Based Eye Drop Formulation B
  • DRUG Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
  • DRUG Carboxymethylcellulose Based Lubricant Eye Drops

Study Locations (1)

California

  • - Petaluma

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2011-10-01
Est. Completion 2012-02-15
Phase Phase 3

Sponsor

Allergan

314 total trials

What the Registry Record Tells You About NCT01459588

The ClinicalTrials.gov registry entry for NCT01459588 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 396-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (20% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 4 interventions - of which Carboxymethylcellulose Based Eye Drop Formulation A is the first listed.

NCT01459588 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01459588 about?

NCT01459588 is a clinical study titled "Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease". This study will evaluate the safety, efficacy, and acceptability of an eye drop formulation in subjects with dry eye disease.

What is the current status of trial NCT01459588?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2011-10-01. Estimated completion is 2012-02-15.

What conditions does trial NCT01459588 study?

This clinical trial studies the following conditions: Dry Eye Syndromes.

What interventions are being tested in trial NCT01459588?

The interventions under investigation include: Carboxymethylcellulose Based Eye Drop Formulation A (DRUG), Carboxymethylcellulose Based Eye Drop Formulation B (DRUG), Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (DRUG), Carboxymethylcellulose Based Lubricant Eye Drops (DRUG).

Who is sponsoring clinical trial NCT01459588?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01459588 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.